CD8A and neoplasm: Additionally, the results from the trial confirmed that NT-I7 promoted TME inflammation by significantly upregulating the CD8+ T-cell to Treg cell ratio and enhanced the antitumor response by increasing the infiltration of IFN-γ-expressing T lymphocytes into the tumor.